NTT-LTD.
4.11.2021 10:02:19 CET | Business Wire | Press release
NTT Ltd. , a global technology and business solutions provider, is today announcing a series of commitments to reduce its carbon footprint and create a connected future that is both more sustainable and inclusive for all. NTT will work to achieve net zero emissions across its operations by 2030 and its value chain by 2040. It is also driving towards powering its Global Data Center Division - an operation of almost 600,000m2 across 20 countries and regions – with 100% renewable energy by 2030 as an urgent priority.
Additionally, NTT is proud to have joined the United Nation’s Race to Zero campaign. This follows the company joining the Business Ambition Pledge for 1.5°C and committing to the Science Based Targets initiative (SBTi). These initiatives are regarded as the gold standard for corporate climate action. They aim to support businesses who are committing to ambitious targets to limit global warming to 1.5°C and avoid the worst effects of climate change.
NTT Ltd.’s Global Chief Executive Officer, Abhijit Dubey, commented, “As one of the largest technology companies in the world, we have an obligation to make the world a more sustainable place. Employees, customers and partners are demanding that companies become more purpose-led. This is core to our NTT heritage, and I am incredibly proud to be announcing our commitment to reach net zero emissions and broader strategic sustainability goals. This is a significant step for us, which will see NTT using technology not only to help the world become more sustainable, but also to be connected long into the future. We will continue making investments in technology, people and programs to achieve these goals.”
NTT’s strategic framework is focused on accelerating sustainable and transformational change across three interconnected pillars:
-
Connected Planet:
- Develop new and expand on existing partnerships to scale technology solutions focused on the protection and regeneration of biodiversity and ecosystems on every continent it operates in support of a more positive future by 2025
- Incorporate circular economy and regenerative design principles working in partnership across its operations, supply chain and client solutions by 2026
- Engage 50% of its employees in conservation and regenerative initiatives in their local communities in support of the UN SDGs and the UN Decade on Ecosystem Restoration by 2025
-
Connected Economy:
- Grow its portfolio of smart solutions to support its clients and partners in decreasing 200m tonnes of greenhouse gas (GHG) emissions by 2026
- Establish a Sustainability Innovation Fund, review board and mentorship program to incubate ideas and scale the impact of climate tech and sustainable solutions and in support of the UN SDGs
-
Connected Communities:
- Ensure that more than 50% of its workforce will belong to one or more of the diversity categories of gender, race, sexual orientation, socio-economic background and disability. To further reinforce this commitment, NTT will double the diversity of its executive leadership team with an emphasis on female representation by 2025
- Provide 5 million young people and children from underprivileged areas across the world with digital access and education to reduce inequality and build critical skills and opportunities for a connected future by 2030
- Enable and empower its employees to contribute 1 million hours of volunteering to support the initiatives forming the three interconnected pillars and in support of the UN SDGs by 2025
Commenting on the NTT’s sustainability commitments, Marilyn Chaplin, Chief Human Resources and Sustainability Officer at NTT Ltd., said, “We know that the greatest opportunity to make a positive impact is through our people, operations, and our core business solutions. This strategic framework gives us clear direction towards making a tangible difference across societies, the economy and our planet. It also provides us with an opportunity to further support our existing initiatives, such as the Connected Conservation Foundation , which uses technology to reduce poaching, and ROBOCEAN , a start-up looking to reduce climate change through the conservation of seagrass. I look forward to working with our talented and diverse ecosystem of stakeholders to help accelerate the change we need to see in the world and making these commitments a reality.”
Visit our website to learn more about our commitment to making the world a more sustainable place.
NTT Ltd. is part of NTT Group, which is committing to zero emissions across its entire group and subsidiaries by 2040.
ENDS
About NTT
NTT Ltd. is a leading global technology services company. Working with organizations around the world, we achieve business outcomes through intelligent technology solutions. For us, intelligent means data driven, connected, digital and secure. Our global assets and integrated ICT stack capabilities provide unique offerings in cloud-enabling networking, hybrid cloud, data centers, digital transformation, client experience, workplace, and cybersecurity. As a global ICT provider, we employ more than 40,000 people in a diverse and dynamic workplace that spans 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.
Visit us at hello.global.ntt
About Business Ambition for 1.5°C:
Business Ambition for 1.5°C is a campaign led by the Science Based Targets initiative in partnership with the UN Global Compact and the We Mean Business Coalition. It was launched in 2019 by a global coalition of UN agencies, business and industry leaders.
About Race to Zero:
Race to Zero is the UN-backed global campaign rallying non-state actors – including companies, cities, regions, financial and educational institutions – to take rigorous and immediate action to halve global emissions by 2030 and deliver a healthier, fairer zero carbon world in time. Led by the High-Level Champions for Climate Action – Nigel Topping and Gonzalo Muñoz – Race to Zero mobilizes actors outside of national governments to join the Climate Ambition Alliance, which was launched at the UNSG’s Climate Action Summit 2019 by the President of Chile, Sebastián Piñera.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005516/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
